Post by Transcell Biologics

𝗣𝗿𝗲-𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗼𝗻 𝗮𝗻𝗶𝗺𝗮𝗹 𝗺𝗼𝗱𝗲𝗹𝘀 𝗶𝘀 𝗮𝗻 𝗮𝗴𝗼𝗻𝗶𝘇𝗶𝗻𝗴𝗹𝘆 𝘂𝗻𝗮𝗰𝗰𝗲𝗽𝘁𝗮𝗯𝗹𝗲 𝗽𝗿𝗼𝗰𝗲𝘀𝘀. AI-enabled Digital Animal Replacement Technology (DART) that leverages human biology and mechanistic insights is a proprietary enterprise solution by Transcell Biologics. It integrates ethically produced, well-characterized relevant human MicroPhysiological Platforms with deep-learning AI analytics for safety/efficacy testing at the early and pre-clinical stages. Traditional animal based testing although, yet it has real limits as animal physiology cannot fully replicate human genetic diversity or human metabolic, immune responses, testing cycles run years, and costs climb into hundreds of millions. 𝗗𝗔𝗥𝗧 𝗶𝘀 𝗯𝘂𝗶𝗹𝘁 𝘁𝗼 𝘀𝗵𝗼𝗿𝘁𝗲𝗻 𝘁𝗵𝗶𝘀 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗰𝘆𝗰𝗹𝗲 𝘄𝗵𝗶𝗹𝗲 𝘆𝗶𝗲𝗹𝗱𝗶𝗻𝗴 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗲𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘂𝗿𝗿𝗼𝗴𝗮𝘁𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘄𝗶𝘁𝗵 𝗮 𝗯𝗮𝗻𝗱𝘄𝗶𝗱𝘁𝗵 𝘁𝗼 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀𝗹𝘆 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲 𝗶𝗻𝘁𝗼 𝗲𝘅𝗶𝘀𝘁𝗶𝗻𝗴 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀.  Upon deployment, the system functions as a decentralized testing workflow within the sponsor's established research and development or quality control framework while eliminating the need for any animal facility infrastructure. With multiple modules undertaking to deliver functional insights like new functions of known drugs, immunogenicity, safety pharmacology, relative potency and more, DART enables a spectrum of applications across the drug/vaccine development process. DART is an industrialised, scalable, human-relevant, and Agentic AI-powered alternative testing platform designed to support the sponsors to prioritize their investments intelligently while accelerating innovation. #DART #NAMs #NewApproachMethodologies #PreclinicalResearch #DrugDiscovery #VaccineDiscovery